gemcitabine has been researched along with piplartine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H; Pan, S; Sun, B; Wang, Y; Wu, X; Zhou, Y | 1 |
| Huang, Q; Qin, G; Tang, T; Ye, W | 1 |
2 other study(ies) available for gemcitabine and piplartine
| Article | Year |
|---|---|
Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Dioxolanes; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer.
Topics: A549 Cells; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cell Survival; Deoxycytidine; Dioxolanes; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Proto-Oncogene Proteins p21(ras); Reactive Oxygen Species | 2021 |